Related Experiment Videos
Critical threshold for dose of myelin basic protein in murine autoimmune encephalomyelitis
Abstract:
The clinical and pathologic features of experimental allergic encephalomyelitis (EAE) in the SJL mouse are described after inoculation with different amounts of myelin basic protein (MBP) in adjuvant. A dose threshold was apparent in that 400 micrograms produced the most severe central nervous system (CNS) changes. These comprised an extensive multifocal destructive myelitis with minimal demyelination. Doses greater than 400 microgram produced less white matter pathology and showed demyelinative rather than destructive lesions. No CNS parenchymal changes were seen in animals given less than 400 micrograms. Inflammation was invariably present in all animals showing CNS pathology, a prominent cellular component of which was the polymorphonuclear leukocyte. These findings illustrate the relationship of clinical signs and pathologic changes to the dose of MBP administered. Thus, it has been shown that the dose requirements for MBP-induced EAE in the SJL mouse are different from and greater than those for other species and that, unlike rats and guinea pigs, lesions were more extensive. Although demyelination was present, lesions tended to be destructive in type. This murine MBP model may serve as an experimental analog for the acute destructive myelopathies occasionally associated with the human autoimmune demyelinating disorders.
Insights
This study reveals that a specific dose of myelin basic protein (MBP) is crucial for inducing experimental allergic encephalomyelitis (EAE) in SJL mice, leading to destructive central nervous system (CNS) lesions and offering a model for human autoimmune demyelinating disorders.
Area of Science:
- Neuroimmunology
- Experimental Pathology
Background:
- Experimental allergic encephalomyelitis (EAE) is a model for autoimmune demyelinating diseases.
- Understanding the dose-dependent effects of myelin basic protein (MBP) is critical for EAE research.
Purpose of the Study:
- To characterize the clinical and pathological outcomes of EAE in SJL mice following inoculation with varying doses of MBP.
- To establish a dose threshold for MBP-induced EAE and analyze lesion characteristics.
Main Methods:
- SJL mice were inoculated with different amounts of MBP in adjuvant.
- Clinical signs and central nervous system (CNS) pathology were assessed.
- Lesion type (destructive vs. demyelinative) and cellular components were analyzed.
Main Results:
- A dose threshold of 400 micrograms of MBP was identified, inducing the most severe CNS changes, characterized by destructive myelitis.
- Higher MBP doses (>400 micrograms) resulted in less white matter pathology and more demyelinative lesions.
- Inflammation, notably polymorphonuclear leukocytes, was present in all affected animals, with no CNS changes observed below the 400-microgram threshold.
Conclusions:
- MBP dose significantly influences EAE severity and lesion type in SJL mice, with a distinct dose requirement compared to other species.
- The SJL mouse model exhibits extensive, destructive lesions, differing from rats and guinea pigs.
- This murine model serves as a valuable analog for acute destructive myelopathies in human autoimmune demyelinating disorders.